

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 May 2019 (23.05.2019)



(10) International Publication Number
WO 2019/096900 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/40 (2006.01)
A61K 31/282 (2006.01) A61P 35/00 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/EP2018/081364

(22) International Filing Date:

15 November 2018 (15.11.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/586,224 15 November 2017 (15.11.2017) US
62/686,149 18 June 2018 (18.06.2018) US
62/733,175 19 September 2018 (19.09.2018) US

(71) Applicant: INNATE PHARMA [FR/FR]; 117 Avenue de Luminy, 13009 Marseille (FR).

(72) Inventors: CHANTEUX, Stéphanie; 430 Avenue Jean de Lattre de Tassigny Résidence Valmont Redon, Bt les Lauriers, 13009 MARSEILLE (FR). GOURDIN, Nicolas; 51 Traverse Pourrière Résidence Les Alizés, Bt A, Appt A13,

13008 Marseille (FR). PATUREL, Carine; 411 Allée du Bois, 69280 Marcy l'Etoile (FR). PERROT, Ivan; Impasse des Brayes Résidence les Brayes, bâtiment la Chaconne, 13260 Cassis (FR). ROSSI, Benjamin; 70 Avenue d'Haifa Résidence la Palmeraie, Bt C, 13008 MARSEILLE (FR).

(74) Agent: VOLLMY, Lukas; INNATE PHARMA, 117 Avenue de Luminy, 13009 MARSEILLE (FR).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: POTENTIATING THE EFFECT OF ATP RELEASE

Figure 13

Oxa Repeated Injections d5, d12



(57) Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 in the treatment of cancer to potentiate the activity of an agent or treatment that induces the extracellular release of ATP from tumor cells and/or induces the death of tumor cells.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*